Log in

NASDAQ:ABMD - ABIOMED Stock Price, Forecast & News

$189.22
+0.15 (+0.08 %)
(As of 12/8/2019 04:00 PM ET)
Today's Range
$187.40
Now: $189.22
$192.11
50-Day Range
$171.91
MA: $196.71
$223.83
52-Week Range
$155.02
Now: $189.22
$364.31
Volume472,636 shs
Average Volume785,882 shs
Market Capitalization$8.54 billion
P/E Ratio52.56
Dividend YieldN/A
Beta0.32
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$769.43 million
Cash Flow$4.00 per share
Book Value$20.78 per share

Profitability

Net Income$259.02 million

Miscellaneous

Employees1,371
Market Cap$8.54 billion
Next Earnings Date1/30/2020 (Estimated)
OptionableOptionable

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.


ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, October, 31st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.93 by $0.10. The medical equipment provider had revenue of $204.97 million for the quarter, compared to the consensus estimate of $206.45 million. ABIOMED had a return on equity of 19.89% and a net margin of 26.92%. The firm's revenue for the quarter was up 12.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.09 EPS. View ABIOMED's Earnings History.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for ABIOMED.

What price target have analysts set for ABMD?

7 analysts have issued 12 month price objectives for ABIOMED's stock. Their forecasts range from $215.00 to $400.00. On average, they anticipate ABIOMED's share price to reach $298.75 in the next year. This suggests a possible upside of 57.9% from the stock's current price. View Analyst Price Targets for ABIOMED.

What is the consensus analysts' recommendation for ABIOMED?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED.

What are Wall Street analysts saying about ABIOMED stock?

Here are some recent quotes from research analysts about ABIOMED stock:
  • 1. According to Zacks Investment Research, "ABIOMED wrapped up fourth-quarter fiscal 2019 on a mixed note. Competition in the MedTech industry is intense. Pricing pressure and foreign currency headwinds persist. ABIOMED has underperformed the industry in a year’s time. However, the company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoption are added positives. Revenues from Japan also skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. In fact, the company continues to invest in training and education. The recent CE Mark of the Impella Connect is encouraging as well. The company’s balance sheet is debt-free." (5/8/2019)
  • 2. BTIG Research analysts commented, "Term; Trimming PT to $340 From $400 Abiomed missed estimates in the quarter, delivering sales of $207M, short of consensus’ $219M forecast. Most of the weakness was U.S. driven, due to a weak cath lab (also seen in peer results) and to a greater extent, mix disruption leading to mgmt’s disproportionate focus away from protected PCI/elective procedures. To reflect these pressures, mgmt’s initial FY20 outlook calls for revenue growth of 17-23%, 6% below what mgmt (and we) would’ve considered more likely (and exactly the exact magnitude of the FQ4 shortfall). Mgmt outlined a number of initiatives to address these issues and noted that April is reportedly promising. The fact that mgmt still remains confident in addressable market and has left room to revise guidance during its next earnings call suggest there is good chance of upside." (5/7/2019)

Has ABIOMED been receiving favorable news coverage?

Media headlines about ABMD stock have been trending somewhat positive on Sunday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ABIOMED earned a news impact score of 2.0 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the stock's share price in the near future. View News Stories for ABIOMED.

Are investors shorting ABIOMED?

ABIOMED saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,630,000 shares, an increase of 25.6% from the October 31st total of 2,890,000 shares. Based on an average daily volume of 604,800 shares, the short-interest ratio is presently 6.0 days. Currently, 8.2% of the shares of the stock are short sold. View ABIOMED's Current Options Chain.

Who are some of ABIOMED's key competitors?

What other stocks do shareholders of ABIOMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Micron Technology (MU), Netflix (NFLX), Intuitive Surgical (ISRG), Square (SQ), bluebird bio (BLUE) and salesforce.com (CRM).

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
  • Dr. David M. Weber, Chief Operating Officer (Age 58)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
  • Mr. William J. Bolt, Exec. Officer (Age 67)
  • Mr. Ian McLeod, VP & Corp. Controller

Who are ABIOMED's major shareholders?

ABIOMED's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (4.39%), Villere ST Denis J & Co. LLC (0.68%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Scout Investments Inc. (0.36%), Kornitzer Capital Management Inc. KS (0.32%) and Marathon Asset Management LLP (0.27%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Which major investors are selling ABIOMED stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Eagle Asset Management Inc., Strs Ohio, Castleark Management LLC, Scout Investments Inc., CIBC Private Wealth Group LLC, Stephens Investment Management Group LLC and Squarepoint Ops LLC. Company insiders that have sold ABIOMED company stock in the last year include David M Weber and Martin P Sutter. View Insider Buying and Selling for ABIOMED.

Which major investors are buying ABIOMED stock?

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, State Street Corp, Villere ST Denis J & Co. LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Kornitzer Capital Management Inc. KS, Rhenman & Partners Asset Management AB and CWM LLC. View Insider Buying and Selling for ABIOMED.

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $189.22.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $8.54 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED.

What is ABIOMED's official website?

The official website for ABIOMED is http://www.abiomed.com/.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  483 (Vote Outperform)
Underperform Votes:  434 (Vote Underperform)
Total Votes:  917
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel